Back to CVE records
Not yet scoredPublished Jul 19, 2026

CVE-2026-63820f2fs: fix missing read bio submission on large folio error

Updated under an hour ago ()

Does this affect you?

It affects Linux. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

In the Linux kernel, the following vulnerability has been resolved: f2fs: fix missing read bio submission on large folio error f2fs_read_data_large_folio() can keep a read bio across multiple readahead folios. If a later folio hits an error before any of its blocks are added to the bio, folio_in_bio is false and the current error path returns immediately after ending that folio. This can leave the bio accumulated for earlier folios unsubmitted. Those folios then never receive read completion, and readers can wait indefinitely on the locked folios. Route errors through the common out path so any pending bio is submitted before returning. Stop consuming more readahead folios once an error is seen, and only wait on and clear the current folio when it was actually added to the bio.

CVSS
Not yet scored
Weakness (CWE)
Not given
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Linux
NVD analysis
Awaiting Analysis
Record last updated
Aug 17, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
Linux Linux
linux:linux (from the name)
from a5d8b9d94e1863f3ebb7182c238b2c713f6f4efd before 48c92559e7b66fdc3cbc74f6e152e66ec0150a0a; from a5d8b9d94e1863f3ebb7182c238b2c713f6f4efd before 74c8d2ec95c59a5651ecd975c466998af1961fd4
CNA record

References

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.